NAMS
Price:
$26.58
Market Cap:
$3.11B
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Industry
Biotechnology
IPO Date
2021-02-09
Stock Exchange
NASDAQ
Ticker
NAMS
According to NewAmsterdam Pharma Company N.V.’s latest financial reports and current stock price. The company's current PE Ratio is -16.72. This represents a change of 8.84% compared to the average of -15.36 of the last 4 quarters.
The mean historical PE Ratio of NewAmsterdam Pharma Company N.V. over the last ten years is -9.43. The current -16.72 PE Ratio has changed 17.63% with respect to the historical average. Over the past ten years (40 quarters), NAMS's PE Ratio was at its highest in in the December 2020 quarter at 1.40K. The PE Ratio was at its lowest in in the March 2020 quarter at -158.86.
Average
-9.43
Median
-9.19
Minimum
-20.05
Maximum
-2.92
Discovering the peaks and valleys of NewAmsterdam Pharma Company N.V. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 213.78%
Maximum Annual PE Ratio = -2.92
Minimum Annual Increase = -68.37%
Minimum Annual PE Ratio = -20.05
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -20.05 | 99.68% |
| 2024 | -10.04 | 93.23% |
| 2023 | -5.20 | -43.28% |
| 2022 | -9.16 | 213.78% |
| 2021 | -2.92 | -68.37% |
The current PE Ratio of NewAmsterdam Pharma Company N.V. (NAMS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-11.76
5-year avg
-9.47
10-year avg
-9.43
NewAmsterdam Pharma Company N.V.’s PE Ratio is greater than Kymera Therapeutics, Inc. (-32.38), less than Viking Therapeutics, Inc. (-7.11), less than Immunovant, Inc. (-14.00), greater than Akero Therapeutics, Inc. (-19.87), less than Crinetics Pharmaceuticals, Inc. (-16.61), greater than Arcellx, Inc. (-28.27), greater than Praxis Precision Medicines, Inc. (-23.23), less than Ligand Pharmaceuticals Incorporated (38.31), less than Soleno Therapeutics, Inc. (27.09), greater than CG Oncology Inc. (-30.99),
| Company | PE Ratio | Market cap |
|---|---|---|
| -32.38 | $8.66B | |
| -7.11 | $3.86B | |
| -14.00 | $7.99B | |
| -19.87 | $4.50B | |
| -16.61 | $8.89B | |
| -28.27 | $6.73B | |
| -23.23 | $8.67B | |
| 38.31 | $6.02B | |
| 27.09 | $2.76B | |
| -30.99 | $6.40B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NewAmsterdam Pharma Company N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NewAmsterdam Pharma Company N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is NewAmsterdam Pharma Company N.V.'s PE Ratio?
How is the PE Ratio calculated for NewAmsterdam Pharma Company N.V. (NAMS)?
What is the highest PE Ratio for NewAmsterdam Pharma Company N.V. (NAMS)?
What is the 3-year average PE Ratio for NewAmsterdam Pharma Company N.V. (NAMS)?
What is the 5-year average PE Ratio for NewAmsterdam Pharma Company N.V. (NAMS)?
How does the current PE Ratio for NewAmsterdam Pharma Company N.V. (NAMS) compare to its historical average?